• JUNE 15, 2000

SmithKline Pharma: A weak prescription

SmithKline Beecham has been undergoing a tough time since the last 12 months. The 38% duty on Engerix its Hepatitis B vaccine coupled with the price control imposed on its B complex vitamin Zevit put paid to the topline growth over the last year.

Its flagship brand Iodex continues to face tough competition from the likes of Paras Pharma’s ‘Moov’, Elder Pharma’s ‘Tiger Balm’ and ‘Amritanjan’.

There have been press reports in the past that the company is introducing its new anti–meningitis vaccine via its 100% subsidiary SmithKline Beecham Asia. Interestingly, this company has no manufacturing facility. Thus it even gets Crocin and Eno (the two other brands under its control) manufactured by SmithKline Pharma which derives a manufacturing fee for the same.

At present, however there are unconfirmed reports of ‘Avandia’ its block buster anti–diabetes drug being introduced through SmithKline Beecham Asia. If these turn out to be true the only source for the company to improve its topline would also vanish.

Particulars (Rs m) FY99 FY00E
Sales 3,295.0 2,636.0
Net Profit 247.0 129.0
EPS (Rs) 8.4 4.4
P/E   33.6

Though the overall pharmaceutical sector is likely to grow by at least 10%, SmithKline Pharma’s topline is expected to show a de–growth of 20% in the current year. The stock quotes at a price of Rs 147 (Rs 445/128) and is unlikely to fly, unless the parent introduces new products through its listed subsidiary.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407